Vilya is a drug developer that aims to use its platform to develop targets that were previously difficult to treat with drugs. The company’s Rosetta platform, powered by machine learning, uses an unknown chemical space to design molecular structures ranging in size between small molecules and antibodies. Due to their drug-like properties, they are able to cross biological membranes and disrupt protein-protein interactions, while being highly selective for their protein targets, making them useful for previously refractory targets in a wide range of indications. Recently, Vilya announced that it has received $50 million in Series A financing, led by ARCH Venture Partners.
This article is reproduced from: https://www.itjuzi.com/investevent/13519389
This site is for inclusion only, and the copyright belongs to the original author.